Browse our comprehensive collection of market intelligence reports.
The amyloid biomarker testing market supports the identification of amyloid pathology associated with Alzheimer’s disease and related neurodegenerative conditions. Demand originates from the need to detect disease progression before significant cognitive decline occurs because therapeutic intervention increasingly depends on biological confirmation rather than symptom-based assessment alone. Healthcare systems are expanding diagnostic pathways as disease-modifying therapies require greater di
The global CNS therapeutics market is expanding because neurological and psychiatric disorders are increasing across aging and metabolically vulnerable populations. Neurodegenerative diseases are creating long-duration treatment dependency since cognitive decline and motor dysfunction require continuous pharmacological management. Healthcare systems are increasing investment in early diagnosis because delayed intervention reduces therapeutic effectiveness in Alzheimer’s disease, Parkinson’s d
The global CNS epidemiology market is expanding because neurological and psychiatric disorders are increasing across aging, urbanized, and metabolically vulnerable populations. Public health systems are strengthening neurological disease surveillance because untreated CNS disorders continue increasing disability-adjusted life years, institutional care dependency, and long-term healthcare expenditure. Epidemiological research is shifting toward longitudinal and real-world evidence models becau
The global CNS diagnostics market is expanding because neurological disorders are increasing across aging and metabolically vulnerable populations. Healthcare systems are prioritizing earlier neurological detection since delayed diagnosis accelerates irreversible neuronal degeneration and increases long-term treatment dependency. Diagnostic demand is shifting toward biomarker-based and imaging-integrated approaches because conventional neurological assessment methods provide limited disease-s
The global Alzheimer’s biomarker testing market is expanding because neurodegenerative disease burden continues increasing across aging populations and healthcare systems are prioritizing earlier cognitive decline detection. Neurology practices are shifting toward biomarker-guided diagnosis because conventional cognitive assessment methods fail to consistently differentiate Alzheimer’s pathology during early disease stages. Blood-based biomarker adoption is accelerating because healthcare sys
The global valvular heart disease market is evolving because aging populations are increasing the prevalence of degenerative valve disorders across both developed and emerging healthcare systems. Demand is shifting toward minimally invasive structural heart interventions because elderly and high-risk cardiovascular patients require lower procedural morbidity and shorter hospitalization duration. This transition is increasing long-term dependence on transcatheter valve replacement systems, ima
The global peripheral artery disease market continues expanding because diabetes prevalence, smoking rates, aging populations, and sedentary lifestyles are increasing long-term vascular disease burden across healthcare systems. Demand is shifting toward minimally invasive endovascular intervention because hospitals increasingly prioritize limb preservation, shorter recovery periods, and reduced surgical complications. This transition is strengthening adoption of drug-coated balloons, atherect
The global hypertension market continues expanding because aging populations, sedentary lifestyles, obesity prevalence, and metabolic disorders are increasing long-term cardiovascular disease burden across major healthcare systems. Demand is shifting toward combination antihypertensive therapies because physicians increasingly prioritize rapid blood pressure stabilization and improved treatment adherence. This transition is strengthening utilization of angiotensin receptor blockers, calcium c
The global heart failure market is expanding as healthcare systems are managing a growing burden of aging populations, metabolic disorders, and recurrent cardiovascular complications. Heart failure treatment demand is shifting toward therapies that reduce hospitalization frequency because payers and providers are facing sustained pressure from long-term disease management costs. Clinical guidelines are increasing dependency on combination therapies, which is strengthening demand for SGLT2 inh
The global atrial fibrillation market is expanding because aging populations, rising cardiovascular disease prevalence, and increasing stroke prevention awareness continue increasing long-term arrhythmia management demand. Healthcare systems are shifting toward earlier rhythm control strategies because recurrent hospitalization and stroke complications continue increasing cardiovascular expenditure across major healthcare economies. This transition is strengthening demand for catheter ablatio
The global atherosclerosis market continues expanding because aging populations, metabolic disease prevalence, obesity incidence, and sedentary lifestyles are increasing long-term cardiovascular disease burden across healthcare systems. Demand is shifting toward preventive cardiovascular management because healthcare providers increasingly prioritize early lipid control and vascular risk reduction. This transition is strengthening adoption of PCSK9 inhibitors, vascular imaging systems, drug-e
The green IT & sustainable computing market is experiencing strong growth. This is because organisations are facing pressure to align digital transformation with environmental responsibility. This market focuses on reducing the environmental impact of IT operations by adopting energy-efficient infrastructure. The market also helps in minimising e-waste and integrating new renewable energy into data centres. The increase in energy demand from data centres is a key driver for the growth of